Transgene (TNG) Resumen de Acciones
Transgene SA, empresa de biotecnología, diseña y desarrolla en Francia vacunas terapéuticas y virus oncolíticos para el tratamiento del cáncer. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
TNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Transgene SA
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €0.83 |
| Máximo en las últimas 52 semanas | €1.50 |
| Mínimo de 52 semanas | €0.58 |
| Beta | 0.73 |
| Cambio en 1 mes | 10.08% |
| Variación en 3 meses | 0.97% |
| Cambio de 1 año | 36.07% |
| Variación en 3 años | -52.89% |
| Variación en 5 años | -72.65% |
| Variación desde la OPV | -98.16% |
Noticias y actualizaciones recientes
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).Recent updates
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...Rentabilidad de los accionistas
| TNG | FR Biotechs | Mercado FR | |
|---|---|---|---|
| 7D | -1.1% | 3.4% | 2.0% |
| 1Y | 36.1% | 344.2% | 1.3% |
Rentabilidad vs. Industria: Los resultados de TNG fueron inferiores a los de la industria French Biotechs, que obtuvo un rendimiento del 344.2% el año pasado.
Rentabilidad vs. Mercado: TNG superó al mercado French, que obtuvo un rendimiento del 1.3% el año pasado.
Volatilidad de los precios
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.9% |
Precio estable de las acciones: TNG no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado French.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TNG (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1979 | 145 | Alessandro Riva | www.transgene.fr |
Transgene SA, empresa de biotecnología, diseña y desarrolla en Francia vacunas terapéuticas y virus oncolíticos para el tratamiento del cáncer. Participa en el desarrollo de TG4050, una vacuna terapéutica que se encuentra en fase II de ensayo clínico para el tratamiento del cáncer de ovario y los cánceres de cabeza y cuello; TG4001, una vacuna terapéutica que se encuentra en fase II de ensayo clínico para el tratamiento de los cánceres positivos al virus del papiloma humano (VPH 16); TG6002, un virus oncolítico que está en fase I/IIa de ensayo clínico para el tratamiento de tumores sólidos, incluido el adenocarcinoma gastrointestinal; y BT-001, un virus oncolítico, que está en fase I/II de ensayo clínico para el tratamiento de tumores sólidos. La empresa también desarrolla TG6050 para el tratamiento del cáncer de pulmón no microcítico, que se encuentra en ensayo clínico de fase I, y Pexa-Vec, un virus oncolítico para el tratamiento de tumores sólidos.
Resumen de fundamentos de Transgene SA
| Estadísticas fundamentales de TNG | |
|---|---|
| Capitalización bursátil | €227.32m |
| Beneficios(TTM) | -€37.52m |
| Ingresos (TTM) | €7.21m |
¿Está TNG sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TNG | |
|---|---|
| Ingresos | €7.21m |
| Coste de los ingresos | €33.90m |
| Beneficio bruto | -€26.69m |
| Otros gastos | €10.84m |
| Beneficios | -€37.52m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
Sep 24, 2026
| Beneficios por acción (BPA) | -0.14 |
| Margen bruto | -370.12% |
| Margen de beneficio neto | -520.44% |
| Ratio deuda/patrimonio | 1.7% |
¿Cómo se ha desempeñado TNG a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 03:48 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Transgene SA está cubierta por 5 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |